Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndamax and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales.
Company facts
| Company | Pfizer Inc. |
|---|---|
| Symbol | PFE |
| Exchange | XNYS |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market cap | $157.60B (Massive market data, 2026-09-10) |
| Employees | 75,000 |
| Country | United States |
| Website | https://www.pfizer.com |
Trading — Pfizer Inc.
| Last price | $27.72 |
|---|---|
| Change | 0.25% |
| Previous close | $27.65 |
| Day range | $27.42 – $27.85 |
| 50-day average | $26.19 |
| 200-day average | $26.21 |
| Average volume | 48,497,567 |
Price basis: 2026-09-11T20:53:46.367170+00:00
Valuation and financial health
| Earnings per share | $0.76 |
|---|---|
| Price / book | 1.85 |
| Price / cash flow | 11.76 |
| Enterprise value / EBITDA | 9.31 |
| Enterprise value / sales | 3.45 |
| Debt / equity | 0.74 |
| Current ratio | 1.27 |
| Dividend yield | 6.21% |
| Free cash flow | $10.99B |
| Cash ratio | 0.03 |
| Enterprise value | $219.81B |
Reported 2026-09-10
Earnings
| Report date | 2026-11-03 |
|---|---|
| Session | Pre Market |
| Fiscal quarter ending | Sep/2026 |
| EPS estimate | $0.79 |
| Year-ago EPS | $0.87 |
| Analyst estimates | 6 |
Source: Nasdaq.com public earnings calendar
Other Healthcare companies
Live data
Live quotes, options positioning, insider and congressional filings for PFE are on the IntelTrends dashboard.